International Network of VENous Thromboembolism Clinical Research Networks

Flag of Canada

CanVECTOR

The Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network is a pan-Canadian, patient-oriented, Community Development Program centred on venous thromboembolism (VTE) related research, training, and knowledge translation.

The purpose of CanVECTOR is to create an enduring, pan-Canadian network of stakeholders, researchers, methodology experts, knowledge transfer experts, research trainees, clinical research professionals, industry partners, public agency partners, healthcare providers, and patient groups whose combined efforts to reduce VTE occurrence, improve VTE diagnosis and therapeutic management, improve the safety of anticoagulant delivery and enhance the quality of life of those impacted by VTE, both in Canada and globally.

Council Members

Gregoire Le Gal

Gregoire Le Gal, MD, PhD

Dr. Le Gal is a Professor in the Division of Hematology of the Department of Medicine at the University of Ottawa, a physician in the Thrombosis Program, Division of Hematology at The Ottawa Hospital, and a Senior Scientist in the Ottawa Hospital Research Institute, Clinical Epidemiology Program.

Dr. Le Gal’s primary research interest is the diagnosis and management of VTE. He has over 200 peer-reviewed publications in general internal medicine and specialized journals. He is a member of the international advisory board of the Journal of Thrombosis and Haemostasis, and a reviewer for main general internal medicine and thrombosis journals. He has been the principal investigator of several multicenter multinational projects on the diagnosis and management of VTE.

Marc Rodger

Marc Rodger, MD, MSc

 Physician-in-Chief and Medical Director of the Medical Mission of the McGill University Health Centre (MUHC). As Physician-in-Chief and Medical Director of the Medical Mission of the MUHC, he oversees 15 general and specialty divisions at the Royal Victoria Hospital, Montreal General Hospital, Lachine Hospital, and Montreal Chest Institute. Dr. Rodger was also appointed this month as a senior scientist in the Cardiovascular Health Across the Lifespan Program at the Research Institute of the MUHC (RI-MUHC).

Dr. Rodger was a hematologist at the Ottawa Hospital from 1998 to 2019, where he also served for a decade as Chief and Chair of the Division of Hematology. He led the development of the Ottawa Blood Disease Centre, which opened in 2012, and founded the Regional Thrombosis Program that provides world-class thrombosis care. As a senior scientist at the Ottawa Hospital Research Institute since 2006, Dr. Rodger co-directed the Canadian Venous Thrombosis Clinical Trials and Outcomes Research Network, which he co-founded, and the International Network of Venous Thrombosis Clinical Research Networks, which he founded.

Dr. Rodger’s research program is focused on venous thrombosis and thrombophilia with specific focus on 1) thrombosis/ thrombophilia in pregnancy and 2) venous thrombosis: optimal management. With over $38 million in peer-reviewed funding (over $22 million obtained as principal investigator) over his lifetime to conduct research in these areas, he has generated over 200 peer-reviewed publications.

Subscribe

* indicates required

Contact Permissions

Please select the ways you would like to hear from INVENT Network:

Contact Permissions

By clicking below to subscribe, you agree to the terms of our privacy policy.